| Outcome Measures: |
Primary: Coronary artery calcification score, 1 year | Secondary: Endothelial function, Measured by EndoPAT™ (Itamar Medical Ltd.), 3 months|Serum bone metabolic markers, Bone specific alkaline phosphatase (BAP) and Tartrate-resistant acid phosphatase 5b (TRACP5b), 3 months|Serum bone metabolic markers, Bone specific alkaline phosphatase (BAP) and Tartrate-resistant acid phosphatase 5b (TRACP5b), 1 year|Serum concentrations of calcium, phosphate, intact parathyroid hormone, 25-hydroxyvitamin D, and 1,25-dihydroxyvitamin D over time, Up to 1 year|Estimated glomerular filtration rate over time, Up to 1 year|Bone mineral density, 1 year|Serum osteoprotegerin concentration, 3 month|Serum osteoprotegerin concentration, 1 year|Urinary alpha-Klotho to creatinine ratio, 3 months|Urinary alpha-Klotho to creatinine ratio, 1 year|Urinary liver-type fatty acid binding protein (L-FABP) to creatinine ratio, 3 months|Urinary liver-type fatty acid binding protein (L-FABP) to creatinine ratio, 1 year|End-stage renal disease requiring renal replacement therapy, Up to 1 year|Cardiovascular event requiring hospitalization, Acute myocardial infarction, angina pectoris, congestive heart failure, stroke, and peripheral vascular disease, Up to 1 year|Death, Up to 1 year | Other: Micro RNA array, 1 year|Hypercalcemia, Corrected serum calcium concentration ≥11.0 mg/dL, Up to 1 year|Hypocalcemia, Corrected serum calcium concentration \<8.5 mg/dL, Up to 1 year
|
